Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novabay Pharmaceuticals (NY: NBY )

0.6810 -0.0237 (-3.36%)
Streaming Delayed Price Updated: 2:49 PM EDT, Jun 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Novabay Pharmaceuticals

< Previous 1 2 3 Next >
NovaBay Pharmaceuticals to Hold Second Quarter 2022 Conference Call on August 11
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Targets New Market with Antimicrobial Avenova® Lid and Lash Spray for Lash Extensions
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals’ DERMAdoctor Products Now Available at Target.com and Urbanoutfitters.com
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Reports Record Avenova® Sales During Amazon’s Prime Day Event
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals’ DERMAdoctor Products to be Featured at Leading B2B Beauty Trade Show Cosmoprof North America
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Reports First Quarter 2022 Financial Results
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Expands Top-Selling DERMAdoctor Kakadu C and Calm Cool + Corrected Collections with New Anti-Aging Formulations
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals to Hold First Quarter 2022 Conference Call on May 12
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals CEO Issues Letter to Stockholders
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin Returns to QVC® to Discuss DERMAdoctor’s Eczema Treatment
From NovaBay Pharmaceuticals, Inc
Via Business Wire
NovaBay Pharmaceuticals Introduces Hydrating Cleansing Oil to its DERMAdoctor Calm Cool + Corrected Product Line
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Reports 2021 Fourth Quarter and Full Year Financial Results
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals to Hold 2021 Fourth Quarter and Full Year Conference Call on March 29
From NovaBay® Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Present DERMAdoctor Eczema Treatment as QVC® On-Air Guest
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Engages Leading Chinese Marketing Firm to Drive Consumer Sales of DERMAdoctor Skincare Products in China
From NovaBay Pharmaceuticals, Inc
Via Business Wire
NovaBay Pharmaceuticals Announces Changes to Its Board of Directors
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals to Donate 2.5 Million KN95 Masks
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Expands Its Eyecare Product Portfolio With the Launch of Lubricating Eye Drops for the Immediate Relief of Dry Eye Symptoms
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Holds Special Meeting of Stockholders
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
DERMAdoctor’s Calm Cool + Corrected Eczema Balm Receives National Eczema Association Seal of Acceptance
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals CEO Issues Letter to Stockholders
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Reports Third Quarter 2021 Financial Results
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Closes DERMAdoctor Acquisition
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Closes $15.0 Million Private Placement
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Announces Pricing of $15.0 Million Private Placement
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals to Hold Conference Call and Webcast With Slide Presentation Today to Discuss Acquisition of DERMAdoctor
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Signs Agreement to Acquire DERMAdoctor
From NovaBay® Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals to Present at the H.C. Wainwright 23nd Annual Global Investment Conference
From NovaBay® Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.